Preview Mode Links will not work in preview mode

Mar 19, 2019

MS is an equal opportunity neurological disease. It doesn't seem to discriminate against any particular ethnic or racial group. It affects Latinos and African-Americans, as well as Caucasians. And if you're an MS research scientist, who's hoping to create a viable treatment that's going to be safe & effective for the diverse population living with multiple sclerosis, then having that diversity represented in your clinical research seems like it would be important. Unfortunately, it doesn't always happen that way. Minority populations are frequently overlooked and under-represented in MS clinical research.
 
My guest on the podcast is Dr. Mitzi Joi Williams, a neurologist and MS Specialist with a strong interest in better understanding the course of MS in ethnic minority populations, and in increasing diversity in clinical research. 
 
Dr. Mitzi Joi Williams 
We're also talking about important MS stem cell research that's being funded by the Department of Defense, the risks associated with stem cell tourism, a new oral Disease Modifying Therapy for relapsing-remitting MS, and a newly-approved prescription medication for treatment-resistant depression.
 
We have a lot to talk about! Are you ready for RealTalk MS?!
 
___________

Promising MS Stem Cell Research Funded by Department of Defense  1:33

National MS Society Announces Strategic Partnership with U.S. Department of Veteran Affairs  4:32

The Risks of Stem Cell Tourism 5:26

Celgene Seeks EMA Approval of Ozanimod  11:29

FDA Approves Esketamine for Treatment-Resistant Depression  12:50

My Interview with Dr. Mitzi Joi Williams  16:27

___________

ADD YOUR VOICE TO THE CONVERSATION

I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes.

Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!

Email: jonstrum@RealTalkMS.com
Phone: (310) 526-2283

___________

LINKS

If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com

Download the RealTalk MS App for iOS

Download the RealTalk MS App for Android

Give RealTalk MS a Rating & Review

Using Reprogrammed Stem Cells as a Therapy for MS

Complications of Stem Cell Tourism in Multiple Sclerosis & Other Neurological Diseases: Results From First Nationwide Survey of Academic Neurologists

Celgene Submits Application to EMA for Ozanimod for the Treatment of Relapsing-Remitting Multiple Sclerosis

FDA Approves Esketamine Nasal Spray for Treatment of Resistant Depression

MS Made Simple by Dr. Mitzi Joi Williams

___________

Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com.

RealTalk MS Episode 82
Hosted By: Jon Strum
Guest: Dr. Mitzi Joi Williams

Tags: MS, MultipleSclerosis, MSResearch, mssociety, Ozanimod, Esketamine, iConquerMS, Stemcells, RealTalkMS

iConquerMS